Mibefradil: A new T-channel selective calcium antagonist

Drugs of Today

Volumn 33, Issue 8, 1997, Pages 523-542

  Kobrin, Isaac ^a   Charlon, Vincent ^a   Lindberg, Elisabet ^a   Neumann, Norbert ^a   Pordy, Robert ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ASTEMIZOLE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; CYCLOSPORIN A; DESIPRAMINE; DILTIAZEM; FELODIPINE; IMIPRAMINE; LACIDIPINE; METOPROLOL; MIBEFRADIL; NICARDIPINE; NIFEDIPINE; NISOLDIPINE; PLACEBO; TERFENADINE; TRICYCLIC ANTIDEPRESSANT AGENT; VERAPAMIL;

ANGINA PECTORIS; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; SINUS BRADYCARDIA; TREATMENT OUTCOME; VERTIGO;

EID: 0030730987     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1997.33.8.432812     Document Type: Review

References (48)

1. Levine, T. The design of the Mortality Assessment in Congestive Heart Failure trial (MACH-1, mibefradil). Clin Cardiol 1997, 20: 320-6.
2. Fleckenstein, A. (Ed.). Calcium Antagonism in Heart and Smooth Muscle. Experimental Facts and Therapeutic Prospects. Wiley & Sons: New York 1983.
3. Wood, A. Calcium antagonists: Pharmacologic differences and similarities. Circulation 1989, 80: IV184-8.
4. Purcell, H., Waller, D., Fox, K. Calcium antagonists in cardiovascular disease. Br J Clin Pract 1989, 43: 369-79.
5. Struyker-Boudier, H., DeMey, J., Smits, J., Nievelstein, H. Hemodynamic actions of calcium entry blockers. In: Clinical Aspects of Calcium Entry Blockers. Van Zwieten, P. (Ed.). Karger: New York 1989, 21-66.
6. Giles, T. Monotherapy with calcium antagonists for mild to moderate primary hypertension. Cardiovasc Drug Rev 1990, 8: 138-54.
7. Haria, M., Wagstaff, A. Amlodipine: A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995, 50: 560-86.
8. 2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol 1989, 13: 754-9.
9. 2+ in dog coronary arterial vascular muscle cells by Ro 40-5967. J Cardiovasc Pharmacol 1994, 24: 1-7.
10. 2+ inward currents by Ro 40-5967 and verapamil: Relation to negative inotropy. Eur J Pharmacol 1991, 196: 205-7.
11. Katz, A. Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol 1996, 28: 522-9.
12. 2+ channel in cardiac tissue. Eur J Pharmacol 1995, 290: 155-8.
13. Orito, K., Satoh, K., Taira, N. Cardiovascular profile of Ro 40-5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood-perfused dog hearts. J Cardiovasc Pharmacol 1993, 22: 293-9.
14. 2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990, 4: 731-6.
15. Ezzaher, A., Bouanani, N., Su, J., Hittinger, L., Crozatier, B. Increased negative inotropic effect of calcium channel blockers in hypertrophied and failing rabbit heart. J Pharmacol Exp Ther 1991, 257: 466-71.
16. 2+ channel antagonist Ro 40-5967 in vascular muscle cells cultured from dog coronary and saphenous arteries. Arch Pharmacol 1993, 348: 191-6.
17. Taira, N. Differences in cardiovascular profile among calcium antagonists. Am J Cardiol 1987, 59: 24B-9B.
18. Schmitt, R., Clozel, J-P., Iberg, N., Buhler, F. Mibefradil prevents neointima formation after vascular injury in rats: Possible role of the blockade of the T-type voltage-operated calcium channel. Arterioscler Thromb Vasc Biol 1995, 15: 1161-5.
19. Andrawis, N., Abernethy, D. Verapamil blocks basal and angiotensin II-induced RNA synthesis of rat aortic vascular smooth muscle cells. Biochem Biophys Res Commun 1992, 183: 767-73.
20. Véniant, M., Clozel, J-P., Hess, P., Wolfgang, R. Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 1991, 17: 277-84.
21. Hagiwara, N., Irisawa, H., Kameyama, M. Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino-atrial node cells. J Physiol 1988, 395: 233-53.
22. Véniant, M., Clozel, J-P., Hess, P., Wolfgang, R. Hemodynamic profile of Ro 40-5967 in conscious rats: Comparison with diltiazem, verapamil, and amlodipine. J Cardiovasc Pharmacol 1991, 18(Suppl. 10): S55-8.
23. Clozel, J-P., Banken, L., Osterrieder, W. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: Comparison with verapamil. J Cardiovasc Pharmacol 1989, 14: 713-21.
24. Billman, G., Halliwill, J., Avendano, C. Effect of calcium channel antagonists on the cardiac vagal tone response to submaximal exercise. Drug Dev Res 1992, 27: 89-106.
25. Guth, B. Reduction of exercise-induced regional contractile dysfunction in dogs using a novel calcium channel blocker (Ro 40-5967). Cardiovasc Drugs Ther 1992, 6: 167-71.
26. Welker, H., Eggers, H., Kleinbloesem, C. et al. Ro 40-5967: Pharmacokinetics of a new calcium antagonist. Eur J Clin Pharmacol 1989, 36: A304.
27. Schmitt, R., Kleinbloesem, C., Osterrieder, W. Ro 40-5967, a calcium antagonist of a new generation? Eur J Clin Pharmacol 1989, 36: A336.
28. Schmitt, R., Kleinbloesem, C., Belz, G. et al. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther 1992, 52: 314-23.
29. Portegies, M., Schmitt, R., Kraaij, C. et al. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris. J Cardiovasc Pharmacol 1991, 18: 746-51.
30. Rousseau, M., Hayashida, W., Van Eyll, C. et al. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocker, mibefradil, in patients with varying degrees of left ventricular systolic dysfunction. J Am Coll Cardiol 1996, 28: 972-9.
31. Van der Vring, J., Bernink, P., Van der Wall, E., Van Velhuisen, D., Braun, S., Kobrin, I. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure. Clin Ther 1996, 18: 1191-206.
32. Rosenquist, M., Brembilla-Perrot, B., Meinertz, T. et al. The acute effects of intravenously administered mibefradil on the electrophysiologic characteristics of the human heart. Eur J Clin Pharmacol 1997, 52: 7-12.
33. Bursztyn, M., Kadr, H., Tilvis, R. et al. Mibefradil, a novel calcium antagonist, in elderly hypertensives: Favorable hemodynamics and pharmacokinetics. Am Heart J 1997, 134: 238-47.
34. Bernink, P., Prager, G., Schelling, A., Kobrin, I. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): A new generation of calcium antagonists? Hypertension 1996, 27: 426-32.
35. Oparil, S., Bernink, P., Bursztyn, M., Carney, S., Kobrin, I. The antihypertensive effects of mibefradil in the treatment of mild to moderate hypertension: Placebo-controlled studies. Am J Cardiol 1997, 80: 12-9C.
36. Carney, S., Wing, L., Ribeiro, A. et al. The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect. J Hum Hypertens 1997, 11: 387-93.
37. Oparil, S., Kobrin, I., Abernethy, D., Levine, B., Reif, M., Shepherd, A. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension. Am J Hypertens 1997, 10: 735-42.
38. Lacourcière, Y., Poirer, L., Lefebvre, J., Archambault, F., Dalle Ave, S., Ward, C. The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension. Am J Hypertens 1997, 10: 189-96.
39. Viskoper, R., Bernink, P., Schelling, A. et al. A randomized, double-blind trial comparing mibefradil and amlodipine: Two long-acting calcium antagonists with similar efficacy but different tolerability profiles. J Hum Hypertens 1997, 11: 459-66.
40. Massie, B., Chrysant, S., Jain, A., Weir, M., Weiss, R., Kobrin, I. Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD. Clin Cardiol 1997, 20: 562-8.
41. Massie, B., Lacourcière, Y., Viskoper, R., Woittiez, A., Kobrin, I. Mibefradil in the treatment of hypertension: Comparative studies with other calcium antagonists. Am J Cardiol 1997, 80: 27-33C.
42. Woittiez, A., Huysmans, F., Bailey, R. et al. A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension. J Clin Nephrology 1997:(In press).
43. Schneeweiss A, Kobrin I, Caspi A, et al. Adding the new calcium antagonist mibefradil to patients on chronic beta-blocker therapy results in improved anti-anginal and anti-ischemic efficacy. Am Heart J 1997, in press.
44. Alpert, J., Kobrin, I., DeQuattro, V., Friedman, R., Shepherd, A., Fenster, P. Additional anti-anginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta-blocker for chronic stable angina pectoris. Am J Cardiol 1997, 79: 1025-30.
45. Bakx, A., Van der Wall, E., Braun, S., Emanuelsson, H., Bruschke, A., Kobrin, I. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study. Am Heart J 1995, 130: 748-57.
46. Braun, S., Van der Wall, E., Emanuelsson, H., Kobrin, I. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: A multicenter placebo-controlled study. J Am Coll Cardiol 1996, 27: 317-22.
47. Tzivoni, D., Kadr, H., Braat, S., Rutsch, W., Ramires, J., Kobrin, I. Efficacy of mibefradil in comparison to amlodipine in suppressing exercise-induced and daily silent ischemia: Results of a multicenter, placebo-controlled trial. Circulation 1997, in press.
48. Davies, G., Kobrin, I., Caspi, A. et al. Long-term anti-anginal and anti-ischemic effects of mibefradil, the novel T-type calcium channel blocker: A multicenter, double-blind, placebo-controlled, randomized comparison with diltiazem SR. Am Heart J 1997, 134: 220-8.